Document:

Letter Agreement

  
 Exhibit No. (10)v

 June 16, 2010 
 Elane Stock

 1101 Rosewood Drive 
 Atlanta, GA
30306 
 Dear Elane: 
 This letter
confirms the offer made to you to work for Kimberly-Clark Corporation. Your initial assignment will be Senior Vice President and Chief Strategy Officer, reporting to me. Your start date with Kimberly-Clark will be August 9, 2010 and you will
assume the Chief Strategy Officer responsibilities on September 1, 2010. 
 Base Salary 

Your starting salary for this position will be $400,000 per year.  
 Annual Incentive 
 You will be eligible to participate in Kimberly-Clark’s
annual incentive plan for management. Your target will be 65% of your base salary. Your bonus payment will be subject to the terms of the Executive Officer Achievement Award Program. For 2010, you will be eligible for a full-year payment based on
actual performance as determined for your position. 
 Long-Term Incentives 

The next regularly scheduled annual equity grant is currently planned for April 2011 and you will be eligible for an award consistent
with your level and performance. The 2010 target long-term incentive award for your level is $490,000. Our mix of equity is currently  1/3 in stock options and  2/3 in performance vested restricted stock. The amount, type and mix of long-term incentive instruments used for the annual long-term incentive grants are subject to change.

 Total Compensation 
 Given the above, your total annual compensation target is $1,150,000. This amount is comprised of your base salary ($400,000), annual incentive target amount ($260,000) and long-term incentive target
amount ($490,000). Again, your total compensation may be higher or lower than the target amount based on company, team and your individual performance. 
 Signing Bonus 
 Effective as of September 1, 2010, you will be granted $250,000
(“Signing Bonus”) of economic value in the form Restricted Stock Units (“RSUs”). The RSUs will vest 100% on September 1, 2013. As a condition of receiving this grant, you will be required to sign a Noncompetition and
Confidentiality Agreement. A copy of this agreement is attached for your review. 
 Benefits and Vacation 

As an employee of Kimberly-Clark, you will be eligible for a benefits program that includes medical, dental, life and accident insurance coverage, along
with an incentive investment plan, paid vacation/holidays and various other benefits. You will be provided information explaining the terms and conditions of these benefit plans. 

  
 1 

  
 You will be extended an executive
severance agreement pursuant to the Company’s Executive Severance Plan subject to approval by the Management Development and Compensation Committee of the Board. This plan provides certain benefits to you upon a change in control and subsequent
loss of your employment. A summary of the key benefits is enclosed. 
 You will receive four weeks of vacation beginning in 2010 and subsequent
years until you are eligible for any additional vacation according to the Kimberly-Clark vacation policy. Unused vacation based on exception will be forfeited at the end of the year and not paid out in cash. 

During Kimberly-Clark’s annual benefits enrollment in the fall, you will have the option to purchase up to one additional week of vacation for the
following calendar year. This option is not available during your initial enrollment at the start of your employment. Purchased vacation is forfeited if not used.
 Office Location 
 Your office will initially be based at our Roswell, Georgia campus.
It is expected that you will spend a significant amount of your time at our Dallas World Headquarters. Accordingly, you will be temporarily assigned to the Dallas office and will have an office there as well. During this temporary period your travel
expenses from your home to Dallas, as well as travel to other locations will be handled under the business travel policy. In June of next year, we will reassess this arrangement and make a determination whether your position needs to be permanently
based in Dallas. If it is determined that Dallas will be the permanent office location Kimberly-Clark will relocate you to Dallas, TX under the terms of Kimberly-Clark’s Relocation Program for U.S. Salaried Exempt Employees
(“Relocation Policy”). A copy of this policy is enclosed. 
 Stock Ownership Guidelines 

Kimberly-Clark has stock ownership guidelines requiring your position to maintain ownership in Kimberly-Clark stock equal to three times base salary. You
are permitted five years to reach this goal. For purposes of determining your ownership, time-vested restricted stock and any shares owned outright are counted. If, at the end of the five years, you are not in compliance with guidelines, your
situation will be reviewed by the CEO. Non-compliance can result in a decreased long-term incentive grant. 
 Conditions of this Offer

 This offer is subject to the completion of the Pre-placement Health History Form, to ensure that you are physically capable of
carrying out the essential duties of your position. If you choose to make us aware that you have a disability under the Americans with Disabilities Act, we would evaluate whether that disability could reasonably be accommodated in regard to those
essential job functions. 
 This offer is also subject to verification that you have the legal right to work in the United States as required by
the Immigration Reform and Control Act of 1986. The Government Form I-9 must be completed within three days of your start date. In addition, you will be required to present certain documentation as part of the required verification process.

 Kimberly-Clark takes great steps to protect from disclosure its confidential and trade secret information. In accordance with our policies,
we expect that as an employee, you will protect any confidential or trade secret information you learn during your employment. In particular, this protection will require that you sign the Confidentiality, Nonsolicitation and Assignment of Business
Ideas Agreement (“Agreement”) as a condition of your employment. The Agreement is required of all new hires at Kimberly-Clark. 

  
 2 

  
 Because your position may involve
access to confidential business information, Kimberly-Clark will perform a pre-placement background investigation. Our offer of employment is contingent upon the results of this background investigation. United States Public Law 104-208 requires we
advise you “that an investigative consumer report including information as to...character, general reputation, personal characteristics, and mode of living” may be made. Upon written request, additional information as to the nature and
scope of the report will be provided. 
 Kimberly-Clark is a drug-free work environment. As a result, an additional condition of this offer is
that you must pass a pre-employment urine drug screening. This drug screening must be completed within five days of acceptance. 
 Because your
prior position(s) may have involved access to confidential business information, this offer is contingent on your ability to satisfy any post-employment restrictions you may have with your prior employer(s) so that you are not hindered in the
performance of the duties of your position by any non-competition or confidentiality agreement. 
 The employment relationship can be ended by
you or Kimberly-Clark for any reason upon appropriate notice. 
 Elane, we look forward to your acceptance of this offer. If you have any
questions or need additional information, please let me know. 
 Sincerely, 
 Thomas J. Falk 
  

			
	Copies:	 	L. Gottung
		 	W. Wada

 There are two copies of the offer letter
enclosed. Please indicate your acceptance of our offer by signing your name on the line below and returning the signed letter to Donna Buchheit in the envelope provided. The other copy is for your records. 

 

	
	 /s/ Elane Stock

	Signature / Date

  
 3Contract Manufacture Agreement

  
 Exhibit 10.1

 FINAL EXECUTION COPY 
 CONTRACT MANUFACTURE AGREEMENT 
 This Agreement (“the
Agreement”) is made on the 27th day of September 2010
between: 
  

	1.	IMMUCELL CORPORATION, a corporation duly organised and existing under the laws of the United States of America having its principal office at 56 Evergreen Drive,
Portland, Maine 04103 USA hereinafter referred to as “the Principal”; 

  

	2.	NORBROOK LABORATORIES LIMITED, a corporation duly organised and existing under the laws of Northern Ireland, having its principal office at Station Works, Newry,
County Down, BT35 6JP, Northern Ireland hereinafter referred to as “the Manufacturer”. 

 WHEREAS:

  

	(A)	The Principal represents that it is the owner of the Product(s) as defined in Schedule 1, and is desirous of entrusting the Manufacturer with their completion and
assembly, as more fully provided herein; and 

  

	(B)	The Manufacturer represents that it has the necessary facilities, equipment, personnel and expertise, and all appropriate or necessary permits, licenses and
certifications for the completion and assembly of the Product(s), as more fully provided herein; and 

  

	(C)	In furtherance thereof the parties hereto have therefore agreed to enter into this Agreement on the terms and subject to the conditions hereinafter contained.

 NOW IT IS HEREBY AGREED in consideration of these presents as follows: 

 

	1.	GENERAL CONDITIONS 

Subject Matter of the Agreement. 
  

	 	1.1	The Manufacturer hereby agrees to incorporate or combine the materials to be obtained by the Manufacturer, as set forth in Schedule 2 hereof, into or with the
materials to be provided by the Principal to the Manufacturer, as set forth in Schedule 2 hereto, in order to complete, assemble and deliver to the Principal the Product(s) as defined in Schedule 1 hereto in conformance with the
specifications set out in Schedule 2 hereto, and in accordance with the terms of this Agreement. 

  

	 	1.2	 The Principal hereby undertakes during the term of this Agreement to purchase the Product(s) exclusively from the Manufacturer and not to perform the
tasks contemplated hereby to be performed by the Manufacturer on its own account, or to have another person or entity perform such tasks, except as otherwise provided in Sections 3.4 and 10 hereof. The Manufacturer hereby agrees that, through the
second anniversary of the Commencement Date (as hereinafter defined) and for so long thereafter as the Principal places timely orders with the 

	 	 
Manufacturer for at least xxxxxxx syringes per Contract Year (as hereinafter defined), the Manufacturer will not assemble, complete, manufacture or otherwise provide services, directly or
indirectly, with respect to or involving Nisin to any persons or entity other than the Principal. Such restriction shall continue in effect xxxxxxxxxxxx following the termination or expiration of this Agreement, other than a termination resulting
from the breach by a Principal of its obligations hereunder. 

  

	 	1.3	The Principal hereby undertakes to ensure that the materials to be provided by the Principal for incorporation into the Product(s), as described in Schedule 2
hereto, will at all times comply with the standard set out for them in the said specifications. 

  

	 	1.4	Unless and to the extent otherwise reasonably directed by the Principal in writing, the Manufacturer shall purchase and warehouse a maximum of twelve (12) months
(or such lesser period remaining in the term of this Agreement) raw materials in accordance with the order forecasts provided for under Clause 2.1 hereto, provided always that the Principal shall be liable for the cost of unused or redundant raw
materials (whether arising due to any change in their specification or on termination of this Agreement (other than termination due to an uncured breach by the Manufacturer, in which event the Principal shall not be so liable)) but such liability
for such costs shall not exceed the cost of twelve (12) months (or such lesser period remaining in the term of this Agreement) raw materials. The Principal shall promptly notify the Manufacturer in the event that its actual requirements for
Products are reasonably expected to differ by more than five (5) batches (as provided in Schedule 1), plus or minus, from any such forecast, and the Manufacturer shall exercise commercially reasonable efforts to adjust its raw materials
inventories accordingly. Payment in respect of any such unused or redundant packaging materials shall be made by the Principal within thirty (30) days of the date of invoice. 

 

	2.	FORECAST AND ORDERS 

  

	 	2.1	In order that the Manufacturer can plan its production and delivery program for the Product(s) the Principal shall provide every six (6) months a good faith
estimate of its requirements for the Product(s) for the subsequent twelve (12) months, such estimates to be broken down on a month by month basis. 

  

	 	2.2	The Principal shall place orders with the Manufacturer subject to a delivery time of at least one hundred and twenty (120) days and provided proper notice has been
given and the Manufacturer is in possession of all information and documents necessary to permit it to proceed to fulfil such order on a timely basis and without interruption, then the Manufacturer shall deliver the Products so ordered to the
Principal, meeting the specifications set forth in Schedule 2, on or prior to the delivery date designated by the Principal in such order. The Manufacturer’s delivery obligation shall be subject to the Principal having delivered to the
Manufacturer, not more than thirty (30) days following the submission of such order, sufficient quantities of the materials to be provided by the Principal for incorporation into such quantity of Products, meeting the specifications for such
materials set forth in Schedule 2 hereto. Such delivery date shall be extended day-for-day by each day beyond such thirty (30) day period that elapses before the Principal has delivered such materials to the Manufacturer.

  

	 	2.3	Any order placed by the Principal will be subject to the minimum order size as set out in Schedule 1 hereto. 

 

	3.	DELIVERY 

  

	 	3.1	Each Order of the Product(s) shall be delivered by the Manufacturer to the Principal at Manufacturer’s premises as identified in Schedule 1 hereto. All
deliveries for the Product(s) shall be based on Free On Board (FOB), Manufacturer’s facility in Newry, Northern Ireland. 

  

	 	3.2	The Manufacturer may at its discretion deliver the Product(s) ordered by the Principal by installments in any sequence, provided that all such installments must be
delivered on or prior to the delivery date established in accordance with Section 2.2 hereof. The Manufacturer shall notify the Principal as soon as practicable as to the dates and quantities of all such installment deliveries. Where the
Product(s) are delivered by installments, each installment shall be deemed to be the subject of a separate contract and no default or failure by the Manufacturer in respect in any one or more installments shall vitiate the Order in respect of the
Product(s) previously delivered or undelivered Product(s). 

  

	 	3.3	If the Principal fails to take delivery of any ordered Product(s) or any part of them and fails to provide any instructions, documents, licences, consents or
authorisations required to enable the Product(s) to be delivered by the Manufacturer, the Manufacturer shall be entitled upon giving written notice to the Principal to store or arrange for the storage of the Product(s) and then risk in the
Product(s) shall pass to the Principal, delivery shall be deemed to have taken place and the Principal shall pay to the Manufacturer all reasonable costs and expenses including storage and insurance charges arising from its failure.

  

	 	3.4	In the event that the Manufacturer fails to deliver any Products on the delivery schedule established in accordance with Section 2 hereof, the Manufacturer shall
(a) deliver such Products as promptly as practicable (unless the Principal has theretofore elected to obtain such Products otherwise and has so notified the Manufacturer in writing, in which event the Manufacturer shall not assemble or ship
such Products to the Principal), and (b) reimburse the Principal for any costs incurred by it arising out of such failure to timely deliver, including without limitation any additional expedited shipping costs incurred by the Principal for
delivery of such Products to customers, or any costs of obtaining replacement Products in excess of the amount payable to the Manufacturer for such Products pursuant to this Agreement. 

  

	4.	NON-COMPLIANCE 

 Where
tests on a batch of the finished goods supplied under this Agreement carried out at the Principal’s laboratory shows that the quality of the batch of the Products does not meet the agreed specification, the Principal may reject such batch,
which the Manufacturer shall replace with Products acceptable to the Principal to be delivered to the Principal within thirty (30) days free of charge, and the Manufacturer shall bear the expense of replacing the raw materials and other
components included in the rejected Products. If the Manufacturer disagrees with the Principal’s determination with respect to such Products’ conformity to specifications, the Manufacturer may have the sealed samples held by the
Manufacturer for the Principal in respect of that particular batch of the Products tested by any independent laboratory as mutually agreed between the parties, whose analysis results shall be final and binding. In the event that such arbitral
analysis shows the relevant batch did comply with the agreed specification as set out in the relevant Certificate of Analysis to be supplied by the Manufacturer in respect of every batch of the Products, the Principal shall reimburse the
Manufacturer for the additional costs incurred by the Manufacturer pursuant to the immediately preceding sentence. The costs incidental to any arbitral analysis will be borne by the Principal if an independent analysis confirms the validity of the
Manufacturer’s certificate and shall be borne by the Manufacturer if the batch is confirmed to be outside the specification as set out in the relevant certificate. The Manufacturer shall carry out all tests on delivered Product within one
(1) month of delivery time (time being of the essence) to satisfy compliance with the relevant Certificate of Analysis. No query or complaint in respect of the Principal’s determination as to Products’ compliance with the
specification shall be considered after such period has elapsed. 
  

	5.	PRICES 

  

	 	5.1	The initial purchase price for the Product(s) shall be as set out in Schedule 1 hereto which said prices shall, subject as hereinafter provided, be applicable
until the second anniversary of the Commencement Date. The parties hereto agree to commence discussions at least three (3) calendar months before such second anniversary and the end of each subsequent Contract Year for the purpose of agreeing
upon prices for the subsequent Contract Year. In the event that the parties are unable to agree upon a price for each Product by the beginning of the next applicable Contract Year, then the price for any such Product will be increased (or decreased,
as applicable). 

  

	 	5.1.1  	by an amount equal to the vouched percentage increase (or decrease, as applicable) in the cost of raw materials or other Product components purchased by the
Manufacturer as provided in Schedule 2; and 

  

	 	5.1.2  	an inflationary price based on increases (or decreases, as applicable) in the (RPI) Retail Price Index as published by the UK Government for the remaining portion of
the relevant price, 

 In both cases calculated from the date of the last price change for the said Product until
the beginning of the next applicable Contract Year. Should either party wish to implement any price increase or decrease under this Clause 5.1 then it shall, at its own cost, produce to the other party a certificate certifying that the amount of the
proposed increase or decrease has been properly calculated in accordance with the requirements of this Clause 5.1. The price calculated in accordance with this sub-clause would apply to all orders placed by the Principal and accepted by the

	 	 
Manufacturer during the following Contract Year. Each party shall cooperate with the other in determining any such price adjustment (or the adjustments contemplated by Section 5.3 hereof),
including, but not limited to, sharing such party’s cost data to the extent relevant to any such calculation. 

  

	 	5.2	All the orders for the Product(s) as supplied by the Manufacturer shall be paid by the Principal in English pounds sterling within thirty (30) days from the date
of the relevant invoice, which shall be delivered upon shipment of such Products. The Manufacturer reserves the right to charge interest on all late payments at a rate of two (2%) percent per annum over Bank of Ireland base rate for sterling,
such interest to be compounded on a weekly basis. 

  

	 	5.3	The Manufacturer reserves the right to increase its prices, subject to providing appropriate documentation thereof to the Principal, at any time to take account of any
sudden increase in any production cost outside its control including the cost of active ingredients, packaging, energy, transport, raw materials or exchange rate fluctuations which may increase the relevant production cost to the Manufacturer by
more than five (5%) percent. The Manufacturer agrees to reduce its prices at any time to take account of any decreases in any of the costs or other factors set forth in the preceding sentence, which may decrease the relevant production cost to
the Manufacturer by more than five percent (5%). 

  

	6.	SUPPLY OF PACKAGING MATERIAL 

  

	 	6.1	The Manufacturer is responsible on his own account for the procurement of all packaging materials used for the manufacturing of the Product(s), in accordance with
Schedule 2 hereof. 

  

	 	6.2	The Principal will supply all artwork and repro film for the making of the packaging materials. All text and art work for the labels, carton and containers to be used
for the Products shall be the sole responsibility of the Principal. The Principal warrants that the text and art work as specified by it complies with the requirements of all the relevant marketing authorisations under which it sells the Products
and the statutory and other legal requirements of each country in which the Products are marketed and sold and furthermore does not infringe any third party intellectual or industrial property rights and hereby indemnifies and shall hold the
Manufacturer harmless against all claims, liabilities and costs accordingly. 

  

	 	6.3	 Unless and to the extent otherwise reasonably directed by the Principal in writing, the Manufacturer shall purchase and warehouse a maximum of twelve
(12) months (or such lesser period remaining in the term of this Agreement) packaging materials in accordance with the order forecasts provided for under Clause 2.1 hereto, provided always that the Principal shall be liable for the cost of
unused or redundant dedicated labels and packaging materials (whether arising due to any change in their specification or on termination of this Agreement) (other than termination due to an uncured breach by the Manufacturer, in which event the
Principal shall not be so liable) but such liability for such costs shall not exceed the cost of twelve (12) months (or such lesser period remaining in the term of this Agreement) materials. The Principal shall promptly notify the

 
Manufacturer in the event that its actual requirements for Products are reasonably expected to differ by more than five (5) batches (as provided in Schedule 1), plus or minus, from any such
forecast, and the Manufacturer shall exercise commercially reasonable efforts to adjust its packaging materials inventories accordingly. Payment in respect of any such unused or redundant packaging materials shall be made by the Principal within
thirty (30) days of the date of invoice. 
  

	7.	LIABILITY 

  

	 	7.1	The Manufacturer agrees to: 

  

	 	7.1.1  	indemnify the Principal against all loss damage or liability suffered by the Principal in relation to any defective Product(s) supplied by the Manufacturer primarily
resulting from any proven negligence or default on the part of the Manufacturer, provided that the Principal shall notify the Manufacturer in writing without delay of any claims made or threatened, give all required information and prompt assistance
and fully co-operate with the Manufacturer in the defence of any action and not take any action nor omit to do anything the result of which may be prejudicial to the Manufacturer in relation to any such matter without first obtaining the
Manufacturer’s written consent, which shall not be unreasonably withheld, delayed or conditioned. 

  

	 	7.1.2  	maintain its own product liability insurance, subject to such insurance being available to it at commercially reasonable rates and terms, in an amount of Sterling
£8,000,000 (eight million British Pounds) (or such other sum as the parties hereto from time to time agree) to cover all loss damage or liability suffered by the Principal in relation to Products resulting from proven negligence or default of
the Manufacturer, provided such liability has not been incurred by the Principal in breach of its obligations under this Agreement. 

  

	 	7.2	The Principal undertakes that it will indemnify and keep indemnified the Manufacturer against all proceedings, costs, liabilities, injury, loss or damage arising
primarily out of the breach or negligent performance or failure of performance by the Principal of the terms of this Agreement, or any defect in the Specifications or other documentation supplied by the Principal to the Manufacturer.

  

	 	7.3	Except as otherwise expressly provided in this Agreement, in no circumstances shall either party be liable in contract, tort (including negligence or breach of
Statutory Duty), or otherwise, and whatever the cause thereof whether reasonably foreseeable or not (a) for any increased costs or expenses, (b) for any loss of profit, business, contracts, revenue, or anticipated savings (c) for any
special indirect or consequential damage of any nature whatsoever. 

  

	 	7.4	Notwithstanding anything contained in this Agreement, under no circumstances shall the Manufacturer be liable to the Principal for any loss or damage whatsoever
suffered by the Principal should the Product licence held by the Principal be suspended, withdrawn or other similar action occurring for whatever reason by the relevant governmental authorities. 

  

	 	7.5	The Principal hereby indemnifies and shall keep the Manufacturer indemnified against any liability arising on the part of the Manufacturer as a “Producer” of
goods for the purposes of the Consumer Protection Act 1987. 

  

	 	7.6	Where the Manufacturer is required to supply the Principal with replacement product arising out of any breach of this Agreement by the Manufacturer in respect of which
any active ingredient, excipient or packaging materials have been supplied by the Principal, then the Manufacturer shall be required to purchase replacement materials from the Principal at the cost for such materials to the Principal.

  

	8.	REGULATORY REQUIREMENTS 

  

	 	8.1	The Manufacturer agrees to assist the Principal by providing access to any necessary document or dossier in its ownership or possession to enable the Principal to make
application to any Regulatory Authority for the Manufacturer to be appointed as Manufacturer of the Product(s) under any marketing authorisation held by the Principal. 

 

	 	8.2	Both parties agree that should any provision in this Agreement be held not to comply with any applicable law regulating the pharmaceutical industry then the parties
hereto shall discuss in good faith such modification to this Agreement to ensure compliance with the relevant laws within the shortest possible time. 

  

	9.	INTELLECTUAL PROPERTY 

  

	 	9.1	It is agreed that all rights to the Product(s) and to any trade or brand name and design used by the Principal in respect of the Product(s) are and shall remain the
exclusive property of the Principal. 

  

	 	9.2	The Principal hereby indemnifies and shall keep indemnified the Manufacturer against all proceedings, costs (including legal costs), liabilities, injury, loss or damage
arising out of any third party claims (whether successful or unsuccessful) relating to ownership of any intellectual or industrial property rights relating to the Product(s) and any trade or brand name or design used by the Principal in respect of
the Product(s). 

  

	10.	FORCE MAJEURE 

 Neither
party hereto shall be liable to the other for any failure to perform or delay in performance of its obligations hereunder (other than an obligation to pay monies) caused by any of the following to the extent beyond the reasonable control of the
party seeking to be excused from performance pursuant to this Section 10: (i) act of God, (ii) outbreak of hostilities, riot, civil disturbance, acts of terrorism, (iii) the act of

 
any government or authority (including but not limited to revocation or suspension of any licence or consent), (iv) fire, explosion, flood, fog or bad weather, (v) default of suppliers
or sub-contractors, (vi) theft, malicious damage, strike, lockout or industrial action of any kind, (vii) inability to obtain supplies of active ingredients, raw materials or packaging (other than due to the cost thereof), or
(viii) machinery breakdown, provided the party so affected shall give prompt written notice to the other party. The party so affected shall exercise diligent, commercially reasonable efforts to mitigate the duration and extent of any such
event, condition or circumstance, shall keep the other party promptly informed as to all developments affecting or relevant to such force majeure, including but not limited to promptly notifying the other party when the cause or causes preventing,
restricting or interfering with its performance hereunder have been eliminated. If the failure or delay occasioned by force majeure subsists for more than one hundred twenty (120) days, either party can terminate this Agreement immediately by
notice in writing to the other party, and, save in respect of any payment due, neither party shall have any liability to the other in respect of the termination of this Agreement as a result of an event of force majeure. During the continuation of
any force majeure event affecting the Manufacturer’s performance under this Agreement, the Principal shall be entitled to take reasonable steps to assure continued supply of the Products, including but not limited to the entry into agreements
with other parties to provide the goods and services to be provided by the Manufacturer hereunder, which agreements may need to extend beyond the termination of the force majeure. In such event, the Principal shall be excused from its obligation to
purchase Products hereunder from the Manufacturer to the extent of the remainder of its obligations under such alternative agreement, notwithstanding the cessation of such force majeure; however, Manufacturer’s obligations under
Section 1.2 hereof shall remain in full force and effect if, but for such force majeure event, Principal would have purchased sufficient quantities hereunder in order for such exclusivity obligations to remain in effect. 

 

	11.	CONFIDENTIALITY 

  

	 	11.1	The parties agree that all rights to any information supplied by the Disclosing Party to the Receiving Party (“Information”) are reserved to the Disclosing
Party and the Receiving Party shall use such Information only for the purpose (hereinafter called “the Purpose”) of exploiting its rights and fulfilling its obligations under this Agreement including without limitation the marketing and
sale of the Products. 

  

	 	11.2	The Receiving Party shall not use such Information except in connection with the Purpose to benefit itself or others and will not communicate such Information to others
except as specifically permitted by this Agreement in connection with the Purpose or if expressly authorised in writing prior to its disclosure to do so in any instance by the Disclosing Party or except as required by applicable law or court order
(of which the Receiving Party shall promptly notify the Disclosing Party). 

  

	 	11.3	The Receiving Party undertakes that such Information will be made available in confidence only to such of its employees and sub-contractors as need to know the same for
the Purpose and such employees are bound by their contracts of employment and such sub-contractors are bound by confidentiality undertakings identical to those contained in this clause not to use or disclose such Information transmitted to them by
the Receiving Party. 

  

	 	11.4  	The Receiving Party undertakes at its own expense to enforce the obligations of confidentiality imposed upon its employees and sub-contractors in accordance with this
clause 11 in so far as they relate to the disclosure of such Information by such employees or sub-contractors. 

  

	 	11.5  	The Receiving Party agrees that such Information shall not be copied or reproduced by it without the express written permission of the Disclosing Party except for such
copies as may be reasonably required for the Purpose of the Receiving Party. 

  

	 	11.6  	The Receiving Party undertakes to prevent disclosure of such Information and the access of unauthorised persons to the Information, and shall be responsible for any
violation of this Section 11 by any of its employees, agents or other persons to whom it makes any of such Information available. 

  

	 	11.7  	The Receiving Party shall in the discharge of its obligations under this clause arrange proper and secure storage for such Information in the form of documents, paper,
computer discs, magnetic tapes or in any other material form. 

  

	 	11.8  	The obligations imposed under this clause 11 shall not apply to such Information if the same: 

 

	 	11.8.1  	was in the public domain at the time it was disclosed or thereafter shall fall in to the public domain except through the default of the Receiving Party its employees,
agents or sub-contractors; or 

  

	 	11.8.2  	was known to and recorded by the Receiving Party prior to its disclosure to the Receiving Party by the Disclosing Party; or 

 

	 	11.8.3  	was disclosed after the express prior authorisation of the Disclosing Party; or 

 

	 	11.8.4  	becomes known to the Receiving Party from a source other than the Disclosing Party without breach of this Agreement the Receiving Party; or 

 

	 	11.8.5  	was independently developed by the Receiving Party without the benefit of any of the Information; or 

 

	 	11.8.6  	is disclosed fifteen (15) years from the time of receipt thereof. 

  

	 	11.9  	If only a portion of such Information falls in any one of the sections under the above clause 11.8 the remainder shall continue to be subject to the prohibitions and
restrictions of this clause 11. 

  

	 	11.10  	No licence or conveyance of any rights to the Receiving Party under any discoveries inventions or patents or to use the Information other than for the Purpose is
granted or implied by the transmission of such Information to the Receiving Party under this Agreement. 

  

	 	11.11  	Notwithstanding anything contained elsewhere in this Agreement the provisions of this clause 11 shall survive the termination or expiry of this Agreement.

  

	12.	ASSIGNMENT AND TRANSFER 

Neither party may assign or transfer its rights or obligations under this Agreement without the prior written agreement of the other, such
agreement not to be unreasonably withheld, other than (a) in connection with the sale or other transfer of all or substantially all of the assignor’s assets, or (b) as collateral in connection with a bona fide debt financing
transaction effectuated by such assignor, as to which no such consent shall be required. Upon any such assignment pursuant to clause (a) under which such assignee agrees to assume all of assignor’s obligations under this Agreement arising
subsequent to the effective date of such assignment, the assignor shall be relieved of any further obligations arising under this Agreement subsequent to the effective date of such assignment. 

 

	13.	TERM AND TERMINATION 

  

	 	13.1  	This Agreement will come into effect on the date first before written and will continue in effect for a period of five (5) years, commencing on the date on which
the Principal submits its first order for Products under Section 2.2 hereof (the “Commencement Date”). Each one (1) year period beginning on the Commencement Date or an anniversary thereof shall be referred to herein as a
“Contract Year.” The parties hereto agree that at least twelve (12) months before the said termination date they shall enter into good faith negotiations for a period of three (3) months with a view to seeking to agree terms for
a new agreement between the parties and having any resultant agreement executed by the parties. 

  

	 	13.2  	In the event of one of the parties being in breach of this Agreement, the non-defaulting party may give written notice to the defaulting party of the breach and
indicate its intention to terminate the Agreement if the breach is not remedied to its reasonable satisfaction within thirty (30) days after receipt for the notice. It shall, at the Principal’s option, constitute a default hereunder which
shall not be subject to remedy or cure if the Manufacturer fails to timely deliver Products hereunder, or delivers Products that do not meet the specifications set forth in Schedule 2 hereto, on three (3) or more occasions, in which
event the Principal shall also be entitled to receive from the Manufacturer whatever damages may be legally available to it, including but not limited to any costs incurred by the Principal in excess of the price payable under this Agreement to
obtain goods and services to replace those to have been provided by the Manufacturer under this Agreement for the remainder of the term of this Agreement in the absence of such termination. 

 

	 	13.3  	The Principal shall be entitled to terminate this Agreement in the event that it has not received from the United States Food and Drug Administration all approvals
necessary in order for the Principal to sell the Products in the United States with no milk discard requirement and the Principal notifies the Manufacturer that it is abandoning its efforts to obtain such approvals. 

  

	14.	AMENDMENTS; ENTIRE AGREEMENT 

 No amendment of this Agreement shall be valid or binding upon the parties hereto unless made in writing and duly executed on behalf of each party hereto. This Agreement constitutes the entire agreement
between the parties with respect to the performance by the Manufacturer of the types of services contemplated by this Agreement, and supersedes any and all prior oral or written agreements, understandings or expressions with respect thereto, which
shall be of no further force or effect. 
  

	15.	NOTICES AND OTHER COMMUNICATIONS 

  

	 	15.1 	Any notice to be served upon or given or communicated to one party hereto by the other (and this clause called “Communication”) shall be in the form of a
document in writing including without limitation facsimile. 

  

	 	15.2 	All communications shall be made to the Manufacturer at the following address: 

 

			
	 Address:
	  	Norbrook Laboratories Limited
		  	Station Works
		  	Newry
		  	County Down
		  	BT35 6JP
		  	Northern Ireland
		  	 Fax: 28 3026 0279
  

	 Attention:
	  	Lord Ballyedmond – Chairman
	
	 and to the Principal at the following address:

 

	 Address:
	  	ImmuCell Corporation
		  	56 Evergreen Drive
		  	Portland
		  	Maine 04103
		  	USA
		  	Fax: (207) 878-2117
	  
 Attention:
	  	Michael Brigham – President and CEO

  

	 	15.3  	All Communications shall be delivered by hand during normal business hours or sent by facsimile or sent by registered post (where possible by airmail).

  

	 	15.4  	A Communication shall have effect for the purposes of this Agreement and shall be deemed to have been received by the party to whom it was made:

  

	 	15.4.1  	If delivered by hand upon receipt by the relevant person for whose attention it should be addressed under Clause 15.2 or upon receipt by any other person then upon the
premises at the relevant time who reasonably appears to be authorised to receive post or other messages on behalf of the relevant party; and 

  

	 	15.4.2  	If sent by facsimile upon the transmission of the Communication to the relevant facsimile number and the receipt by the transmitting facsimile machine of an answer back
code showing that the facsimile message has been received properly by the facsimile machine to which it was transmitted; and 

  

	 	15.4.3  	If sent by registered post seven (7) days after the date upon the registration receipt provided by the relevant postal authority. 

 

	 	15.5  	Each party shall be obliged to send a notice to the other (in accordance with this clause) of any change in the details for it recorded in clause 15.2 which details
shall be deemed to have been amended accordingly. 

  

	16.	REASONABLENESS 

 The
provisions of this Agreement are considered by the parties hereto to be reasonable in all the circumstances and accordingly it is hereby agreed that if any restriction herein contained shall be judged to be void as going beyond what is reasonable in
all circumstances but would be valid if part of or all of the wording were deleted or modified or the periods thereof reduced or the extent of the restriction reduced in scope the same restrictions shall apply with such deletions or modifications
and shall be necessary to make them valid or effective. 
  

	17.	SEVERABILITY 

 In the
event that any one or more of the provisions contained in this Agreement shall for any reason be held to be unenforceable illegal or otherwise invalid in any respect under the laws governing this Agreement or its performance and cannot be modified
in accordance with Clause 16 hereto, such unenforceability, illegality or invalidity shall not affect any other provisions of this Agreement and this Agreement shall then be construed as if such unenforceable illegal or invalid provisions had never
been contained herein. 
  

	18.	NOTIFICATION OF AGREEMENT 

In so far as this Agreement or any matters relating to it may be notifiable to the EC Commission for the purposes of obtaining an
exemption under Article 85(3) of the EEC Treaty or for any other reason, the parties hereto agree that the Principal shall be responsible for any such notification and the Manufacturer authorises the Principal to conduct any such notification and
any matters relating to it for that purpose, subject to the Principal being obliged to consult with the Manufacturer at each stage relating to the preparation for notification, the actual notification and any matters arising therefrom. 

  

	19.	DISPUTES, PROPER LAW AND JURISDICTION 

 The parties hereto shall strive to resolve on an amicable basis any dispute that may arise between them relating to the terms of this Agreement failing which the parties shall agree to submit any dispute
to the exclusive jurisdiction of the High Court of Northern Ireland. The Agreement shall be subject to the laws of Northern Ireland. 

SIGNED by duly authorised representatives of each of the parties hereto on the date first before written. 

SIGNED on behalf of NORBROOK LABORATORIES LIMITED: 

	
	
	/s/ Ballyedmond
	Signature
	
	 
	Name
	
	 
	Position

 SIGNED on behalf of IMMUCELL
CORPORATION: 
  

	
	
	/s/ Michael F. Brigham
	Signature
	
	Michael F. Brigham
	Name
	
	President and CEO
	Position

  
 SCHEDULE 1

  

							
	 Products
	  	 Minimum Order Size
	  	 Initial Purchase Price
	  	 Destination

	Mast Out ®	  	Minimum Annual Order Quantity	  	See table below	  	Manufacturer’s
		  	xxxxxxxxxxxxxxxxxxxxxx for the	  		  	facility in Newry,
		  	first Contract Year; all of	  		  	Northern Ireland
		  	Principal’s requirements for	  		  	
		  	Products in subsequent Contract	  		  	
		  	Years	  		  	
		  	Minimum Batch xxxxxxxxxxx	  		  	
		  	xxxxxxxxxx (each, a “batch”)	  		  	

 FOB Newry, Northern Ireland 
 PURCHASE PRICE (U.S. DOLLARS) 
  

			
	 Order Volume
	  	 Cost per Syringe

	 xxxxxxx
 xxxxxxxxxxxxx
 xxxxxxxxxxxxxx

xxxxxxxxxxx
	  	 xxxxx
 xxxxx
 xxxxx
 xxxxx

  
 SCHEDULE 2

 Responsibilities of the Parties 

 

							
	 ITEM
	 	 RESPONSIBILITY

	 Section A. Formulation and Chemical Raw Materials
	 	 Norbrook
	 	 ImmuCell

	A1	  	 (Active ingredients and excipients)
 Unit Formulation for Product
	 		 	ü
	A2	  	Quality Specification of Raw Materials in Product Formulation	 		 	ü
	A3	  	Analytical Methods for Testing of Raw Materials	 		 	ü
	A4	  	Purchase and supply of Nisin API to Norbrook Free of Charge	 		 	ü
	A5	  	Purchase of Raw Materials for Manufacture of Product	 	ü	 	
	A6	  	Inspection and Release of Raw Materials for Manufacture of Product	 	ü	 	
	A7	  	Retention of Reference Samples of Raw Materials	 	ü	 	
	A8	  	Retention of Analytical Testing Records	 	ü	 	
			
	 Section B. Manufacture of Product
	 	 Norbrook
	 	 ImmuCell

	B1	  	Manufacture of Product	 	ü	 	
	B2	  	Quality Control Specifications for Bulk Product	 		 	ü
	B3	  	Analytical Methods for Testing of Product	 		 	ü
	B4	  	Retention of Batch Manufacturing Records	 	ü	 	
	B5	  	Manufacturing instructions including in-process controls	 	ü	 	
			
	 Section C. Packaging for the Product
	 	 Norbrook
	 	 ImmuCell

	C1	  	Master Filling and Packaging Instructions	 		 	ü
	C2	  	Quality Control Stipulations for Packaging Components	 		 	ü
	C3	  	Purchase and Supply of Packaging Components	 	ü	 	
	C4	  	Inspection and Release of Packaging Materials for Use	 	ü	 	
	C5	  	Retention of Samples of Packaging Components	 	ü	 	
	C6	  	Filling, Labelling and Packaging of Product Including In-Process Controls and Inspections	 	ü	 	
	C7	  	Retention of Batch Packaging Records	 	ü	 	
			
	 Section D. Finished Product
	 	 Norbrook
	 	 ImmuCell

	D1	  	Finished Product Specifications and Analytical Methods	 		 	ü
	D2	  	Inspection of Product and Release for Shipment to Customer	 	ü	 	
	D3	  	Inspection and Final Release of Product for Sale	 		 	ü
	D4	  	Retention of Reference Samples of Finished Product	 	ü	 	
	D5	  	Retention of Analytical Testing Records	 	ü	 	
	D6	  	Contents of Certificate of Analysis	 	ü	 	
	D7	  	Finished Product Sample Requirements	 		 	ü

  

							
	 ITEM
	 	 RESPONSIBILITY

	 Section E. Quality control
	 	 Norbrook
	 	 ImmuCell

	E1	  	Pharmacovigilance	 		 	ü
	E2	  	Investigation of complaints	 	ü	 	ü
	E3	  	Action of complaints	 	ü	 	
	E4	  	Recording of complaints	 	ü	 	ü
	E5	  	Product Recall	 	ü	 	ü
	E6	  	Annual product quality review	 	ü	 	ü
	E7	  	Follow-up stability studies	 		 	ü
			
	 Section F. Operations to be Carried Out by Third Parties
	 	 Norbrook
	 	 ImmuCell

	H1	  	Analytical Product Testing to be Performed by Third Parties	 	N/A	 	N/A
	H2	  	Manufacturing Operations to be Performed by Third Parties	 	N/A	 	N/A
			
	 Section G. Miscellaneous
	 	 Norbrook
	 	 ImmuCell

	I1	  	Supply of Safety Data	 		 	ü
	I2	  	Retention of Product Distribution Records	 	ü

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]